Drug Discovery Informatics Market - US$ 8.01 Billion by 2031 | Growing at a CAGR of 12% through 2024-2031 North America Leads with 42% Share Key Players Charles River Laboratories, Certara, Oracle

The Global Drug Discovery Informatics Market reached US$ 3.11 billion in 2023 and is expected to reach US$ 8.01 billion by 2031, growing at a CAGR of 12% during the forecast period 2024-2031. The market is gaining strong momentum as pharmaceutical and biotechnology companies increasingly adopt data-driven approaches to accelerate drug development timelines, reduce costs, and improve success rates.

Drug discovery informatics integrates advanced computational tools, big data analytics, machine learning, and predictive algorithms to analyze vast biological datasets, simulate molecular interactions, and identify promising drug candidates. These technologies enable researchers to model complex biological processes and optimize lead selection more efficiently. Market growth is further supported by rising investments in artificial intelligence-enabled platforms; for instance, in September 2024, Xaira Therapeutics selected Oracle Cloud Infrastructure (OCI) to strengthen its AI-driven drug discovery and development capabilities, underscoring the growing reliance on scalable cloud and AI technologies to transform the drug discovery landscape.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/drug-discovery-informatics-market?sai-v

The Drug Discovery Informatics Market is the sector that provides computational tools, software, and data platforms to accelerate and optimize the drug discovery and development process.

Key Developments
✅ December 2025: Pharmaceutical and biotechnology companies expanded adoption of AI-driven drug discovery informatics platforms to accelerate target identification, lead optimization, and predictive toxicity assessment.

✅ October 2025: Integration of cloud-based informatics, big data analytics, and machine learning enhanced collaboration, scalability, and efficiency across global drug discovery workflows.

✅ August 2025: Advances in in silico modeling, molecular simulation, and virtual screening improved hit-to-lead success rates and reduced early-stage R&D costs.

✅ June 2025: Growing use of real-world data, omics databases, and bioinformatics tools strengthened data-driven decision-making in preclinical drug discovery.

✅ March 2025: Increased investment in cheminformatics and bioinformatics solutions supported faster compound screening and improved pipeline productivity.

Mergers & Acquisitions
✅ December 2025: A leading life sciences software provider acquired a drug discovery informatics or AI startup to expand its end-to-end computational drug development capabilities.

✅ October 2025: Strategic partnerships formed between informatics platform developers and pharmaceutical companies to co-develop AI-powered discovery and analytics solutions.

✅ August 2025: Drug discovery informatics firms collaborated with CROs and research organizations to integrate computational tools into outsourced R&D services.

✅ June 2025: Cloud technology providers entered alliances with drug discovery informatics companies to enhance data security, scalability, and compliance.

✅ March 2025: Academic institutions and early-stage informatics startups partnered to translate novel algorithms and bioinformatics methods into commercial drug discovery applications.

Key Players
Certara | Charles River Laboratories | Collaborative Drug Discovery, Inc. | Eurofins DiscoverX | Jubilant Biosys Ltd. | Selvita | Chemaxon Ltd. | Oracle | IBM

Key Highlights

Certara - Holds a share of 15.7%: Specializes in biosimulation, model-informed drug development, and regulatory-grade software platforms that accelerate decision-making across drug discovery and development.

Charles River Laboratories - Holds a share of 18.9%: Provides end-to-end drug discovery and preclinical services, including in vitro, in vivo, and safety assessment solutions supporting pharmaceutical R&D.

Collaborative Drug Discovery, Inc. - Holds a share of 6.4%: Delivers cloud-based data management and collaboration platforms enabling efficient sharing and analysis of drug discovery data.

Eurofins DiscoverX - Holds a share of 11.8%: Focuses on target-based drug discovery services, cell-based assays, and pharmacology screening to support early-stage drug development.

Jubilant Biosys Ltd. - Holds a share of 12.6%: Offers integrated drug discovery services including medicinal chemistry, biology, and informatics for global pharmaceutical clients.

Selvita - Holds a share of 9.3%: Provides comprehensive drug discovery and preclinical development services with strong expertise in oncology and immunology.

Chemaxon Ltd. - Holds a share of 5.9%: Develops cheminformatics and molecular modeling software supporting compound design, property prediction, and virtual screening.

Oracle - Holds a share of 7.5%: Supplies cloud infrastructure, data management, and analytics platforms enabling scalable drug discovery and life sciences informatics.

IBM - Holds a share of 5.1%: Supports drug discovery through AI-driven analytics, cloud computing, and advanced data platforms enabling predictive modeling and research insights.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=drug-discovery-informatics-market?sai-v
(Purchase 2 or more Reports and get 50% discount)

Market Drivers
- Growing demand to reduce drug development timelines and R&D costs across pharmaceutical and biotechnology companies.

- Increasing adoption of AI, machine learning, and big data analytics in drug target identification and lead optimization.

- Rising complexity of biological data generated from genomics, proteomics, and high-throughput screening technologies.

- Expanding use of in silico modeling, virtual screening, and molecular simulation tools.

- Increasing focus on precision medicine and targeted drug development approaches.

- Rising collaborations between pharma companies and informatics solution providers.

- Supportive government funding and increasing investment in digital drug discovery platforms.

Industry Developments
- Development of AI-driven platforms for target discovery, lead identification, and drug repurposing.

- Integration of cloud-based informatics solutions for scalable data management and collaboration.

- Expansion of predictive analytics and modeling tools to improve candidate selection and success rates.

- Growing partnerships between pharmaceutical companies, CROs, and informatics technology providers.

- Increased use of real-world data and multi-omics datasets in drug discovery workflows.

- Rising mergers, acquisitions, and strategic investments in drug discovery informatics companies.

- Advancements in automation and workflow integration across discovery and preclinical research.

Regional Insights
North America - 42% share: Driven by strong pharmaceutical R&D presence, high adoption of AI technologies, and robust investment in drug discovery innovation.

Europe - 30% share: Supported by advanced research infrastructure, strong academic-industry collaborations, and increasing digitalization of drug development.

Asia Pacific - 22% share: Fueled by growing pharmaceutical manufacturing, rising R&D spending, and rapid adoption of bioinformatics and AI tools.

Latin America - 4% share: Boosted by expanding clinical research activities and gradual adoption of digital drug discovery platforms.

Middle East & Africa - 2% share: Driven by increasing investments in life sciences research, digital transformation initiatives, and emerging biotech ecosystems.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/drug-discovery-informatics-market?sai-v
Key Segments

➥ By Function
Clinical Trial Data Management: Platforms designed to collect, manage, integrate, and analyze clinical trial data, improving data quality, regulatory compliance, and trial efficiency.

Molecular Modeling: Computational tools used to simulate molecular structures and interactions, supporting target identification, lead optimization, and rational drug design.

Sequence Analysis Platforms: Bioinformatics solutions for analyzing genomic and proteomic sequences to identify mutations, biomarkers, and therapeutic targets.

Docking Studies: Software tools used to predict the binding affinity and interaction between drug candidates and biological targets, accelerating virtual screening and lead selection.

Others: Includes cheminformatics, pharmacokinetic and pharmacodynamic modeling, systems biology, and data visualization tools.

➥ By Solution
Software: Standalone and cloud-based platforms providing modeling, simulation, data analytics, and bioinformatics capabilities for pharmaceutical and biotechnology research.

Services: Professional and managed services including data analysis, modeling support, platform customization, and consulting to support drug research and development activities.

➥ By Application
Drug Discovery: Use of computational tools to support target identification, hit-to-lead development, virtual screening, and early-stage optimization of drug candidates.

Drug Development: Applications focused on preclinical and clinical development, including trial design, safety assessment, efficacy modeling, and regulatory submission support.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.